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1, This review focuscs on the extracellular actions of 
ATP and adenosine, and in particular their role in 
cardiovascular regulation.
2, ATP serves as a co-transmitter within the sympa­
thetic nervous system, and is also released from 
endothelium and aggregating thrombocytes. ATP 
acts on P2x purinoceptors on vascular smooth 
muscle cells to induce vasoconstriction. Stimulation 
of P2y purinoceptors on endothelial cells releases 
endothelium-derived relaxing factors and causes 
vasodilatation. This dual action of ATP may have 
pathophysiological importance by inducing 
vasospasm at sites of impaired endothelial function 
and thrombus forma lion.
3. Adenosine is generated by enzymic degradation 
of ATP. Its formation is enhanced during ischaemia. 
Adenosine inhibits noradrenaline release from 
sympathetic nerve endings, causes vasodilatation 
via endothelium-dependent and endothelium- 
independent actions, has important anti-arrhythmic 
properties and prevents deleterious sequelae of 
ischaemia. In humans, adenosine evokes a 
sympatho-excitatory reflex mediated by chemically 
sensitive receptors and afferent nerves in the 
kidney, heart and forearm. This reflex may he active 
during exercise and ischaemia and, because of its 
potential adverse consequences, it should be 
considered when developing new therapies to poten­
tiate the anti-ischaemic actions of endogenous 
adenosine in humans. Adenosine appears to 
mediate ischaemia-induced pain; a reduced sensi­
tivity to adenosine may underlie silent ischaemia.
4. New drugs that interact with adenosine forma­
tion or degradation or with adenosine receptors are 
under development. These have potential thera­
peutic application in the treatment of ischaemia 
and other circulatory disorders.
INTRODUCTION
The cardiovascular actions of extracellular nucleo­
sides and nucleotides have been recognized since 
the beginning of this century [1], but a comprehen­
sive understanding of their interstitial formation, 
degradation and mode of action and their (patho)- 
physiological significance has only recently been 
accomplished [2], They appear to be involved in 
modulation of central nervous system actions, 
immune function, thrombocyte aggregation and 
regulation of renal and gastrointestinal homoeo- 
stasis, and may influence virtually every body 
function through their interaction with the 
autonomic nervous system [3], This review will focus 
on the extracellular actions of two purines: adeno­
sine and ATP, and in particular their role in the 
modulation of the cardiovascular system. Although 
purine receptors in the brain may contribute to
ressurc refutation, we o *<»/* /vi
beyond the scope of this review.
FORMATION, RELEASE AND DEGRADATION OF 
ADENOSINE AND ATP
Within the cell, culenositit’ is primarily formed by 
two metabolic routes [4J. One is from ATP, by 
degradation, via ADP and AMP to adenosine. This 
pathway is accelerated when there is a mismatch 
between energy supply and demand and probably 
represents the main route of adenosine formation 
during ischaemia, The hydrolysis of AMP is 
catalysed by ^'-nucleotidase, which is present both 
in the intracellular (cytosolic form) as well as the 
extracellular space (membrane-bound form). In the 
second pathway, adenosine is formed by hydrolysis 
of ATP via A’-adenosylmethioninc to tV~adenosyl-
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homocysteine which in turn is hydrolysed to adeno­
sine. This reaction is catalysed by .V-adenosylhomo- 
eysteine hydrolase. This route is oxygen insensitive 
and is probably of minor im portance during 
ischaemic conditions. Adenosine diffuses through 
the cellular m em brane between the extracellular and 
intracellular space. This bidirectional process [5] is 
gradient dependent and is facilitated by a nucleoside 
transporter that is located in the plasma m em brane 
of many cells such as the endothelial cells, erythro­
cytes, cardiomyocytes and vascular smooth muscle
I \
A part from a cellular source of adenosine, adeno­
sine formation may occur from extracellular ATP 
that can be degraded rapidly to adenosine by 
ectonucleotidases which are widespread and present 
on the extracellular surface of vascular smooth 
muscle cells and endothelium  [6]. The endothelium 
appears to play a key role in uptake and metabolism 
of luminally applied adenosine [7], but it is also a 
major source of endogenous adenine nucleosides 
and nucleotides. The endothelial release of adenine
sosides and nucleotides is increased by 
/¿-adrenergic stimulation [6], Noradrenaline-induced 
activation of 5 '-nucleotidase may play a role in this 
interaction between endothelial adenosine form a­
tion and the sympathetic nervous system [8].
ATP is released by exocytosis from aggregating 
thrombocytes and from sympathetic nerve endings 
where it is co-released with noradrenaline [3, 9]. In 
most cells, cytoplasmic ATP concentrations are high 
and simple diffusion of ATP through the cell 
m em brane may partly account for extracellular ATP. 
During increased blood flow [10], sympathetic nerve 
stimulation [ 11], or application of well-known 
vasodilators like bradykinin and acetylcholine [12], 
endothelial cells appear to release ATP. Cardiac 
isclniemia evokes an increase in plasma nucleotide 
concentration in the venous effluent which is under­
estimated by vascular eetonueleotidase activity [6 ],
During normal oxygenation, intracellular adeno­
sine and AM P concentrations are low. In this situa­
tion, extracellular adenosine will be transported 
rapidly to the intracellular com partm ent where it is 
further inactivated by phosphorylation to A M P or 
deamination to inosine. An extracellular form of
adenosine deaminase exists. Intracellular deam ina­
tion after uptake is probably of greater importance 
in humans [13],
PURINERGIC RECEPTORS
Cardiovascular responses to purines are mediated 
by m em brane-bound receptors that are subdivided 
into Pi- and p 2-purinergic receptors (Table 1) 
[14]. This subdivision is based on the potency order 
of agonists (A T P  >  A D P >  A M P >  adenosine and 
adenosine >  A M P > A D P >  ATP for the IV  and 
Pi-purinergic receptor respectively), the Pi- but not 
P2-purinergie receptor antagonistic properties of 
xanthine derivatives, and differences in intracellular 
second messengers [15].
Pi-purinergic rcceptors were originally subdivided 
into Ai and A 2 , receptors. This differentiation has 
been verified by molecular techniques [16], Both 
receptors are linked to G-proteins, A 1-receptor 
stimulation evokes a Gi-mediated decrease in 
adenylate cyclase activity with subsequent reduction 
in intracellular cAMP levels. Ai receptors are linked 
to o ther effector systems (phospholipasc C, potas­
sium and calcium channels [17, 18]). A i-receptor- 
m ediated  opening of KATP-channels [19] may play a 
role in the phenom enon of ischaemic precondi­
tioning (see below). The A 2 receptor is associated 
with a Gs binding protein and stimulation of this 
receptor increases adenylate cyclase activity with a 
subsequent increase in intracellular cAMP levels. 
Recently, the existence of a distinct A 3 adenosine 
receptor has been demonstrated [20]. This receptor 
is less sensitive to antagonism by methylxanthines 
and can be stimulated specifically by a synthetic 
adenosine derivative, N6-2-(4-aminophenyl)ethyIade- 
nosine (A PN EA ). Like the other adenosine recep­
tors, the A 3 receptor is coupled to a G-protein. 
Stimulation of the A3 receptor reduces the intra­
cellular cAM P concentration. In pithed rats, intra­
venous infusion of APNEA evokes a hypotensive 
response which is mediated by mast cell degranula­
tion [21], In the rabbit heart this receptor has been 
implicated in ischaemic preconditioning (see below) 
[22]. Advances in molecular biology will probably 
reveal many o ther subclasses of the adenosine
Table I. Classification of purine receptors
Main class Most potent endogenous ligand Subclass Structure Type
Pi Adenosine Ai Cloned G-proteln coupled
Aja Cloned G-protein coupled
A2b Cloned G-protein coupled
A3 Cloned G-protein coupled
P2 ATP P2X Cloned Ligand-operated cation channel
ATP Ply Cloned G-proteln coupled
UTP P*. Cloned G-protein coupled
ADP Pt Not known G-protein coupled
ATP1* P2 Not known Non-selective pore
Api - ¿A Pd Not known Not known
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receptor whose specific pharm acological or physio­
logical effects, distinct from  Ai- or A a-reccptor 
stimulation, will need to be elucidated.
The vascular IVpurinorgic recep tor has been 
subdivided into P2x- and P2y-purincrgic receptors 
based on rank-order differences in agonist potencies 
and different vascular effects (Table 1) [23]. The 
existence of a separate vascular ‘pyrimidine* or 
‘nucleotide’ receptor with affinity for both  A T P and 
UTP has also been suggested [24, 25]. W hether this 
represents a distinct, so-called Fsu-purinergic 
receptor, or is a mem ber of the VPay purinocep tor 
family' [26] depends on w hether U TP acts as its 
endogenous ligand [27], Based on pharm acological 
evidence, a further subdivision of P ^- and Pay-pur- 
inoceptors has been proposed [26, 28].
A m ore definite characterization of cardiovascular 
Pa-receptors is hindered by the lack o f selective, 
competitive receptor antagonists [27]. T he  Pax-pur- 
incrgic receptor agonist, a,/i-methylene ATP, has 
been successfully applied to perform  radioligand 
studies on P2 purinoreceptors and to desensitize 
P2x-pu.rinergic receptors [29, 30]. A lthough desensiti­
zation with a,//-methylene A T P may 
antagonize P2x-purinoceptor-mediated responses in 
vitro, repeated  application of a,//-m ethylene A T P  in 
vivo not only inhibits the vasoconstrictor effect of 
ATP, b u t may also a ttenuate  the vasoconstrictor 
effect o f noradrenaline, angiotensin II and 
vasopressin [31]. In addition, the ability of 
a,//-methylene ATP to inhibit A TP-induccd  effects 
varies enormously [32]. Suram in has been  reported  
to inhibit P2x purinoceptors. However, this drug also 
inhibits the Pay purinoceptor and several enzymes 
including possibly eetophosphatases [33, 34], A 
classification of P2 purine receptors, based on 
potency differences between various A T P deriva­
tives, can be confounded by differences in deg rada­
tion of ligands by eetophosphatases [35].
A Pay-like receptor with seven transm em brane 
domains has been isolated from  turkey and chicken 
brain bu t is not expressed in the heart [36, 37], A 
P211 receptor has been cloned from hum an airway 
and colonic epithelium [38], This receptor also 
contains seven m em brane-spanning dom ains, 
characteristic of G-protein-eoupled receptors, bu t is 
expressed in the heart. Two pharmacologically and 
structurally different Pax-purinergie receptors have 
been cloned from rat vas deferens and phaeoehro- 
moeytoma PC 12 cells [39, 40]. As anticipated from 
voltage-dam p studies, both receptors are ligand- 
gated ion channels. Thus, m olecular techniques 
confirm a heterogeneity of Pa purinoceptors as 
anticipated by pharmacological observations,
A part from vascular Pa-purinergie receptors, 
specific Parpurinergie receptors have been  dem on­
strated on thrombocytes [41]. A DP is the most 
potent endogenous agonist fo r this recep tor and 
ATP is an endogenous antagonist 
stimulation results in throm bocyte activation and 
subsequent thrombus formation. A selective and
possibly competitive antagonist of this receptor has 
been synthesized [43], In the future, this may have 
clinical im portance as an anti-throm botic agent. 
Stim ulation by A T P 4" of a Pa* purinoceptor in 
non-excitable cell types such as leucocytes, parotid 
acinar cells and 3T6-transform ed fibroblasts induces 
non-sclective pores and may be involved in cell 
fusion [44, 45]. Finally, a Pad purinoceptor has been 
recognized with diadenosine polyphosphates (Ap/,A; 
n =  3 -6 )  as endogenous ligands. Ap<iA is stored in 
synaptic vesicles and chromaffin granules and may 
play a role as a co-transm itter in the nervous system 
[46], This receptor (class?) has not been fully 
characterized. Som e of the described effects of
diadenosine polyphosphates may be m ediated by 
o ther P2 receptors [46, 47]. W hen more structural 
data, as obtained from m olecular techniques, and 
truly selective antagonists becom e available, major 
changes in this classification of P2 purinoceptors will 
probably occur. As yet, no generally accepted classi­
fication system for Pa purinoceptors exists [27],
CARDIOVASCULAR EFFECTS OF PURINERGIC 
RECEPTOR STIMULATION
Vascular wall
ATP exerts two vascular actions that are opposite 
and m ediated  by two distinct Pa-purinergic receptors 
located on endothelium  and vascular smooth muscle 
cells (Table 2), The endothelial receptor evokes an 
endothelium -m ediated  vasodilator response (Fig. I) 
[49], O n vascular sm ooth muscle cells, Pax-purinergie 
recep to r stim ulation results in a vasoconstrictor 
response [50] that has also been observed in human 
vessels in vitro [51], but since the endothelium  plays 
an im portan t role in degradation and uptake of 
purines, only a m inor part of luminally applied ATP 
will probably reach the vascular smooth muscle cells 
[52], Indeed, if endothelial function is intact, A TP as 
released during thrombocyte aggregation causes 
vasodilatation [53]. The receptor on vascular smooth 
muscle cells will preferentially be stimulated by 
uUerstitially released A TP as occurs from sympa­
thetic nerve endings (Fig. 1). Biochemical, histo- 
chemieal, eleetrophysiologieal and pharmacological 
evidence supports the hypothesis that ATP is 
released from sympathetic nerve endings, together 
with noradrenaline [3, 54]. In the mesenteric 
vascular bed of the rat, subthreshold doses of ATP 
poten tia te  the vasoconstrictor response to noradre­
naline but not to 5'-hydroxytryptamine or potassium 
chloride, indicating a specific facilitating 
synaptic interaction between ATP and noradrena­
line [55]. A direct, endothelium-independent* 
relaxing effect of ATP on vascular sm ooth muscle 
cells has also been observed, suggesting the presence 
o f  P2v purinoceptors [56, 57].
W hen infused into the brachial artery of healthy 
hum ans, A TP induces a dose-dependent vasodilator 
response, with high concentrations inducing maximal
16 G, A. Rongen et al,
Receptor
subtype
Ai
Aja
Ab (?) [48]
Aîi,
A3
Pî;
P2:
P2u
Pat
P2ï
P2d
Table 2, Cardiovascular effects of purine receptor stimulation
<> * n I % (<# , m. V *C‘- 14 .T'.' ^ -< < »» V • ** ' '  •*
Tissue distribution
Juxtaglomerular cells
Sympathetic efferent nerves
Sympathetic afferent nerves
Smooth muscle cells in glomerular afferent
arterioles and possibly in pulmonary vascular bed
Cardiac conduction system
Cardiomyocytes 
Vascular smooth muscle cells 
Thrombocytes 
Endothelium
Not expressed in cardiovascular system
Vascular smooth muscle cells 
Cardiomyocytes 
Endothelial cells 
Vascular smooth muscle cells 
Sympathetic efferent nerves (?)
Endothelial cells
Vascular smooth muscle cells
Thrombocytes
No known distribution in cardiovascular system 
Endothelial cells (Apa-^ A)
Vascular smooth muscle cells (Aps-&A)
Effect of receptor stimulation
Inhibition of renin release 
Presynaptic inhibition of neurotransmitter release 
Autonomic reflex with sympatho-excitation 
Vasoconstriction
Depression of sinus node activity, prolongation of atrioventricular 
conduction time, attenuation of Ischaemia- and catecholamine- 
induced arrhythmias 
Reduction of contractility 
Vasodilatation
Inhibition of thrombocyte aggregation 
Release of EDRF
Hypotensive effect In rats has been related to
mast cell degranulation
Vasoconstriction
Increase in contractility
Release of EDRFs
Vasodilatation
Inhibition of neurotransmitter release
Release of EDRFs
Vasoconstriction
Thrombocyte aggregation
May be involved in macrophage fusion
Release of EDRFs
Vasoconstriction
vasodilatation, indicating that the  vasodilator action 
of luminally applied ATP is not limited by stimula­
tion of P2x purinoceptors or the release of 
endothelium-derived contracting factors [58]. These 
responses to ATP could not be inhibited by 
theophylline and the vasodilator response to ATP 
was approximately 10 times more potent than the 
vasodilator response to equimolar doses o f adeno­
sine, indicating that Pi purinoeeptor activation is not 
responsible for the vasodilator response to ATP
[58].
Adenosine induces a vasodilator response via 
Aa-purinergic receptor activation in most vessels 
(see Fig. I) [59]. Although the Ai-purinergic 
receptor may mediate vascular relaxation via 
opening of A T P-dependent potassium channels [18], 
this receptor subtype is generally believed to be 
involved in a vasoconstrictor action of adenosine in 
glomerular afferent arterioles (see below) and 
possibly also in the pulmonary vascular bed [60]. In 
humans however, only a vasodilator response to 
adenosine in the  pulmonary vascular bed has been 
described [61].
An intact endothelium  is not obligatory for the 
vasodilator action of adenosine [62], but because 
some studies show a reduced vasodilator response to 
adenosine when the endothelium is removed, adeno­
sine receptors may be present on these cells [49]. 
Inhibition of nitric oxide synthase has been shown to 
inhibit adenosine-m ediated vasodilatation [63],
tly, As-adenosine receptors have been 
dem onstrated on human endothelial cells [64], but
there is som e debate with regard to their functional 
significance. The site of adenosine application or 
form ation may determine whether the vasodilator 
response is mediated by a direct effect on the 
vascular sm ooth muscle cells (interstitial adenosine) 
or w hether the endothelium is involved (luminal 
adenosine) [65]. In humans, infusion of adenosine 
into the brachial or coronary arteries results in 
vasodilatation [66, 67]. The latter serves as the basis 
for the adenosine stress test for inducible ischaemia 
in patients undergoing this test for the evaluation of 
coronary artery disease [68]. This vasodilatation can 
be antagonized by caffeine and theophylline, 
indicating a Pirpurinoceptor-mcdiated effect. Nitric 
oxide participates in this vasodilator response [69], 
supporting a role for the endothelium in the 
vascular action of intraluminally applied adenosine 
in vivo .
Ai purinoceptors are also reported to mediate a 
vasodilator effect via opening of ATP-dependent 
potassium  channels [18]. This potassium channel can 
also be activated by stimulation of A 2 purinoceptors 
[70]. W e have not been able to dem onstrate a role 
for A TP-dependent potassium channels in the 
forearm  vasodilator response to adenosine in 
hum ans [69].
A part from their direct influence on vascular 
tone, purines inhibit noradrenaline release from 
sympathetic nerve endings by presynaptic modula­
tion (see Fig. 1). Most studies on this subject point 
towards an adenosine-induced Ai-purinergic 
receptor-m ediated mechanism. ATP, via yet unclas-
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sided purinergic recep tor subtypes (P :y and a 
possible Pj purinoceptor), may be involved as well 
[71, 72]. Using nucleoside transport inhibition to 
increase adenosine concentrations at sites of fo rm a­
tion, we recently dem onstra ted  presynaptic m odula­
tion of noradrenaline release from sympathetic 
nerve endings in hum ans in vivo [73].
Based on the experim ental data above, Burnstock 
and Sneddon [3] hypothesized that ATP is 
co-released with noradrenaline  by sympathetic nerve 
endings, induces a vasoconstrictor response in 
concert with noradrenaline and is rapidly degraded 
to adenosine which presynaptieally inhibits sympa­
t i c  neurotransm itter release thus providing a
negativc-fcedback loop. T h e  activity o f this feedback 
loop may be controlled by eetonucleotidase activity
[74].
Heart
In addition to causing coronary vasodilatation and 
presynaptic inhibition of noradrenaline  release, 
purines have negative chronotropic, drom otropic
and inotropic effects in isolated heart preparations, 
A T P is thought to induce its negative chronotropic 
and drom otropic effects after degradation to adeno­
sine [75]. However, under certain experimental 
conditions, atropine or vagotomy can attenuate 
these actions, indicating that this effect is at least 
partially vagally m ediated  [76].
igative chronotropic actions. Adenosine 
depresses sino-atrial node activity and shifts the 
earliest site of atrial activation from the sino-atrial 
node towards the crista terminalis region. At high 
concentrations, adenosine may even cause sino-atrial 
exit block. Adenosine may also depress atrioventric­
ular and ventricular escape rhythms. In patients with 
a ventricular escape rhythm, heart rate is reduced in 
response to adenosine, especially when the escape 
rhythm is accelerated by isoproterenol. These effects 
are probably m ediated by A i-adenosine receptor 
stim ulation [77], In the atrium, this receptor is 
id  via a G -protcin to an acctylcholine- 
dependen t potassium channel. Activation of this 
channel results in hyperpolarization of pacemaker 
cells and subsequent reduction in the frequency of 
depolarizations [78]. In the intact organism, the
Sympathetic nerve ending
L-arginine + 02 " '—»■ L-cîtrulline + NO
NOsynthase
[Ca2+] ♦
other 
EDRFs ?
Adenosine
ATP
Fig» I. Schematic presentation of the vascular cffccts of adenosine and ATR Abbreviations: NE, noradrenaline; EDRF, 
endothelium-derived relaxing factor; EDCF, endothelium-derived contracting factor; NO, nitric oxide.
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adenosine-induced stimulation of reflex mechanisms 
may result in an increase in heart rate, which 
strongly contrasts with its effect on the sino-atrial 
node (see below).
Negative dromotropic actions. Adenosine prolongs 
atrioventricular conduction time in a
dependent manner. Its site of action is probably the 
proximal portion of the atrioventricular junction. 
Based on the rank order of potency of different 
adenosine analogues and the use of specific antago­
nists, A i-adenosine rceeptors are thought to be 
involved [79, 80]. The ability of adenosine to induce 
atrioventricular block has led to its widespread 
clinical use in the diagnosis and treatment of broad 
complex tachycardias [81, 82). Bolus infusions are 
used for this purpose to prevent the reflexly induced 
sympathetic excitation that occurs when adenosine is 
infused more slowly [83].
(Anli-)arrliythinic properties. Adenosine can atten­
uate ischaemia- and catecholamine-induced arrhyth­
mias in experimental preparations [84, 85] via 
Ai-adenosine receptors, probably by preventing 
catecholamine-induced calcium influx and subse­
quent afterdepolarizations [77]. ATP also inhibits 
isoproterenol-induced calcium influx, probably by 
stimulating Ai-adenosine receptors after its degrada­
tion to adenosine [77], When ATP alone (i.e. 
without isoproterenol pretreatm ent) is applied to 
isolated myocardial cells, calcium influx is increased. 
This effect is thought to be related to Pa-purinergic 
receptor stimulation [86] and may contribute to 
ATP-induced automatieity. Alternatively, in isolated 
myocardial cells, ATP hydrolysis may activate the 
chloride/bicarbonate exchanger. The ¡? 
intracellular acidification may induce arrhythmic 
activity, providing a Pz-purinergic receptor-indepen­
dent mechanism [87].
'wntive inaimmc actions. Adenosine has a
negative Inotropic effect on both atrial and 
ventricular myocardium when contractility is 
increased with isoproterenol, probably by antago­
nizing the isoproterenol-induced increase in intra­
cellular eAMP [77]. In the atrium, adenosine also 
has a direct, i.e. without isoproterenol pretreatm ent, 
negative inotropic action, probably by increasing 
potassium efflux and subsequent hyperpolarization. 
These effects are mediated by Ai-adenosine 
receptor stimulation [77]. fn contrast to adenosine, 
ATP exerts a positive inotropic action on both atrial 
and ventricular myocardial cells [88] by increasing 
the intracellular calcium concentration.
Kidney
In contrast to most other vascular beds, adenosine 
induces A i-reeeptor-m ediated vasoconstriction in 
the outer renal cortex that appears to be confined to 
the glomerular afferent arterioles. Simultaneously, 
adenosine dilates the efferent glomerular arterioles 
via Aa-adenosine receptor stimulation [89], Acting in
concert, these effects of adenosine lower glomerular 
filtration rate. The vasoconstrictor effect occurs 
immediately upon adenosine infusion, while the 
vasodilator response develops more slowly, 
opposing effects of adenosine may explain the 
biphasic response of renal blood flow but a constant 
ression of glomerular filtration rate during 
infusion of adenosine into the renal artery [89], In 
the rat kidney, adenosine and angiotensin II act 
synergistically on  afferent glomerular arterioles [90 
Adenosine-induced release of endothelium-derived 
relaxing factor (ED RF) probably contributes to the 
efferent arteriolar vasodilatation [91]. Inhibition of 
tubuloglom erular feedback by selective adenosine 
receptor antagonists and adenosine deaminase, as 
well as its stimulation by adenosine deaminase 
inhibition and nucleoside transport inhibition, is 
im portant evidence in favour of adenosine as a 
m ediator of these phenomena [2].
A denosine inhibits renal renin release via 
A i-adenosine receptor stimulation [92, 93], resulting 
in reduced angiotensin II production and subse­
quent aldosterone release. Renal erythropoietin 
production is increased by Az-adenosine receptor 
stimulation [94].
T he renal effects of ATP  are less well assessed. In 
the rat, A T P induces a vasoconstrictor response that 
appears to be most pronounced in afferent (preglo- 
m erular) arterioles. The efferent arterioles are not 
affected by A TP [95]. ATP may also be involved in 
tubuloglom erular feedback [96]. Mesangial cells 
contain Pi y purinoceptors [97], but their physio- 
logical role is, to our knowledge, not clear.
The direct tubular effects of purine receptors are 
beyond the scope of this review.
EFFECTS OF ADENOSINE ON AFFERENT NERVE 
ENDINGS
In conscious humans and some animals, adeno­
sine stimulates carotid and aortic chemoreceptors 
83] and afferent nerves in the kidney [98], heart 
[99, 100] and forearm muscle [101]. Stimulation of 
these afferent nerves activates the sympathetic 
nervous and respiratory systems [102, 103), causing a 
subsequent increase in systolic blood pressure, 
plasma renin activity and ventilation [83, 104, 105]. 
The increase in heart rate is probably mediated by 
concom itant deactivation of the parasympathetic 
nervous system, since it can be antagonized by 
atropine but no t by propranolol [106], These excita­
tory effects of intravenous adenosine infusion are
on an intact autonomic reflex arc [83], 
which probably explains why these effects arc 
blunted in anaesthetized humans [107]. An increase 
in systolic blood pressure is not always observed 
during intravenous infusion of adenosine into 
healthy volunteers [108, 109], probably due to differ­
ences in the degree of their caffeine abstinence. In 
the studies in which no increase in systolic blood
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pressure is observed, caffeine abstinence is invari­
ably brief or totally absent. A fter ingestion of two 
cups of regular coffee, plasma caffeine concentra­
tions are in the range of 4 - 5  mg/1 [1.10], which is 
sufficiently high to antagonize the haemodynamic 
effects of intravenous adenosine infusion [104], The 
plasma half-life time of caffeine after ingestion of 
two cups of coffee ranges from  2 to 8.5 h [110]. 
Therefore, a 24 h period of caffeine abstinence is 
important to prevent underestim ation of adenosine- 
induced haemodynamic and neurohum oral effects. 
An increase in systolic blood pressure, heart rate 
and plasma catecholamines has also been observed 
in resting man after administration of the adenosine 
transport inhibitor dipyridamole [111]. 
changes could be inhibited by previous administra­
tion of caffeine or theophylline [ 111, 112], 
suggesting that adenosine is form ed under baseline 
conditions and has functionally im portant actions. 
These effects of endogenous adenosine have 
recently been replicated by the m ore selective 
nucleoside transport inhibitor draflazinc [113]. The 
excitatory effects of dipyridamole might explain its 
lack of benefit on cardiovascular mortality in large
trials [11.4, 115],
In the heart and skeletal muscle, stimulation of 
adenosine-sensitive afferent nerves induces 
ischaemia-likc pain [116]. W hether anginal pain and 
sympathetic activation arc elicited by stimulation of 
the same afferent nerves is unknown. In healthy 
volunteers, sympatho-cxcitation is a m ore sensitive 
marker of adenosine-sensitive afferent nerve stimu­
lation than the induction of chest discomfort [113]. 
In patients with atherosclerotic heart disease, intra­
coronary infusion of adenosine can mimic both the 
nature and location of ischaemic pain [117], 
suggesting that adenosine may be the chemical 
mediator of angina in this condition. Chest pain is 
not provoked when adenosine is infused into 
patients with total cardiac afferent denervation, i.e. 
orthotopic cardiac transplant recipients [118]. In 
contrast to subjects with intact cardiac innervation, 
systolic blood pressure falls in these transplant 
patients, suggesting that a significant contributor to 
the sympatho-cxcitation observed when adenosine is 
infused in normal subjects is a reflex response to 
stimulation of adenosine-sensitive cardiac afferent 
nerve endings [99, 1 19, 120].
Patients with coronary artery disease manifest a 
spectrum of responses to ischaemia, from chest 
discomfort to a total lack of awareness. The 
syndrome of silent ischaemia, in which no chest pain 
is experienced, has attracted considerable attention, 
but the mechanism responsible for this variation in 
the expression of ischaemia between subjects, and 
within the same subject on different occasions, 
remains uncertain. The severity of chest pain in 
response to intravenous adenosine infusion is
somewhat less in those with predominantly silent 
ischaemia than in subjects who experience angina 
[121J, but the role of endogenously formed adeno­
sine in this variable perception of ischaemia is as yet 
unexplored. As the extent o f myocardium exposed 
to ischaemia may have a bearing on whether o r not 
this stimulus is perceived as pain [122], there may be 
a quantitative relationship betw een the am ount of 
adenosine generated  and the development of 
angina. Alternatively, silent ischaemia may be 
caused by selective loss of adenosine-sensitive 
cardiac afferent nerves (certainly silent ischaemia is 
associated with autonom ic neuropathy in patients 
with diabetes mellitus [123]), or by decreased 
responsiveness of receptors on these afferent nerve
endings to adenosine. We are pursuing
these latter hypotheses.
A part from sympathetic afferent nerves, the heart 
contains adenosine-sensitive vagal afferent nerves 
that are located in the inferoposterior wall of the 
left ventricle [124]. Stimulation of these afferent 
nerves may explain a recent observation that the 
effect of dipyridamole infusion on heart ra te  is 
related  to the site of the perfusion defect on
thallium scanning -  with attenuation of the heart 
rate response in patients with inferoposterior, as 
opposed to anterior left ventricular hypoperfusion 
(A, Zahedi, J. S. Floras and R. J. Burns, unpub­
lished work).
ADENOSINE: A NATURAL DEFENCE AGAINST THE 
CONSEQUENCES OF ISCHAEMIA
Extracellular form ation of adenosine is increased 
during hypoxia and ischaemia [125]. Several effects 
of locally form ed adenosine are assumed to be 
beneficial in situations of reduced oxygen supply 
[126], In the heart, its negative inotropic and chron­
otropic effects will reduce oxygen demand, and 
adenosine-induced vasodilatation will increase 
oxygen supply. Its clectrophysiologieal actions 
should reduce the risk of ischaemia-induecd arrhyth­
mias. Endogenous adenosine inhibits noradrenaline 
release and sympathetic neurotransmission during 
ischaemia [127, 128]. Presynaptic inhibition of 
noradrenaline release should attenuate catechola­
mine-induced arrhythmogenesis, vasoconstriction, 
thrombocyte aggregation and cytotoxicity [129], In 
addition, adenosine inhibits thrombocyte aggrega­
tion [130] and may reduce the formation of leuco­
cyte-derived free radicals during ischaemia and 
reperfusion [131]. In several animal models, adeno­
sine has been shown to reduce myocardial infarct 
size, prevent ischaemia-induced cardiac arrhythmias 
and reduce myocardial stunning [132-134],
Adenosine appears to be involved in precondi­
tioning, defined as the increased tolerance of 
myocardium to a prolonged ischaemic insult, 
achieved by an initial brief exposure to ischaemia 
and reperfusion [ 135]. Preconditioning probably 
occurs in humans [136]. In animals, adenosine- 
induced preconditioning is m ediated by Ai receptors 
[137], An A j-adenosine receptor may also be
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involved [22]. P ro tein  kinase G appears to play a key 
role in the post-receptor mechanism of precondi­
tioning [138], although interspecies differences exist 
in the im portance of protein kinase C in ischaemic 
preconditioning [139]. Activation of protein kinase 
C facilitates opening of A TP-dependent potassium 
channels, which are im portant in mediating 
ischaemic preconditioning [132, 140]. Alternative 
proteins that play a role in ischaemic precondi­
tioning and whose function could be modulated by 
protein  kinase C activation are ecto-5'-nucleotidase 
and the  nucleoside transporter [141-144], The role 
of nitric oxide in ischaemic preconditioning is not
understood [144, 145], Recently, 
ischaemic preconditioning has also been dem on­
strated  in skeletal muscle of the pig [146] and in the 
brain [147], indicating that rhythmic contractions are 
not obligatory for this phenom enon and suggesting 
that this protective m echanism against the sequelae 
of ischaemia might also be operative in patients with 
in term ittent claudication or with cerebral ischaemia. 
A denosine recep to r stimulation and elevation of 
endogenous adenosine levels appear to reduce 
cerebral infarct size [148] and mediate cerebral 
ischaemic preconditioning [147] in animals. A deno­
sine a ttenuates  the  synaptic release of the cytotoxic 
amino acids g lu tam ate and aspartate by stimulation 
of presynaptic A i-adenosine receptors. Postsynapti- 
cally, adenosine depresses membrane calcium 
perm eability and increases potassium and chloride 
permeability, resulting in hyperpolarization and a 
reduced oxygen dem and  [149]. Endogenous adeno­
sine prevents the occurrence of convulsions [150], 
D ilation of cerebral arterioles will increase oxygen 
supply.
The role of the  sympathetic nervous system in 
ischaemic preconditioning is controversial. In 
rabbits, p re trea tm en t with reserpine prevents 
ischaemic preconditioning from reducing infarct size 
[151]. N oradrenaline  is able to augment ischaemia- 
induced adenosine form ation by activation of 
5 '-nucleotidase [8], Furtherm ore, noradrenaline
adenosine) has been shown to induce 
ischaemic preconditioning [8], In contrast, ischaemic 
preconditioning occurs in cultured human 
myocardial cells, a  model that lacks sympathetic 
innervation [152], In the isolated perfused rat heart, 
ischaemic preconditioning reduced noradrenaline 
release during sustained ischaemia (‘neural precon­
ditioning’) [153], U nlike the beneficial effects of 
ischaemic preconditioning on infarct size, this reduc­
tion in noradrenaline release could not be attributed 
to endogenous adenosine release and could only 
partially be prevented by inhibitors o f protein kinase 
C. These authors suggested a ro le for neural precon­
ditioning in m ediating the  anti-arrhythmic effect of 
ischaemic preconditioning.
D espite the increasing am ount of evidence that 
adenosine is beneficial in cardiac ischaemia, some 
conflicting results should also be mentioned. While 
in animals infusion of the adenosine receptor
*\ r a
antagonist 8-phcnyltheophylline in combination with
deaminase exacerbates myocardial 
ischaemia during exercise [154], in humans admini­
stration of theophylline, aminophylline or bamiphyl- 
line may reduce exercise-induced ischaemia as 
assessed by electrocardiographic param eters [155, 
156]. Recently, this apparent discrepancy has been 
clarified. Aminophylline has ai-adrenoceptor 
agonistic properties which redistribute myocardial 
flow during mild ischaemia in favour of the suben­
docardial myocardium [157, 
ischaemia in this area. However, during severe 
ischaemia, aminophylline exacerbates myocardial 
injury, probably by antagonizing the cardioprotective 
effects of endogenous adenosine [157]. In the rat 
heart, ischaemic preconditioning may not be 
mediated by «-adrenoceptors or adenosine receptors 
[159]. In the kidney, adenosine only marginally 
affects renal blood flow (due to a combination of 
afferent arteriolar constriction and efferent vasodila­
tation) but reduces tubular oxygen demand by a tten­
uating glomerular filtration rate and tubular 
function [160], Notwithstanding, the adenosine 
receptor antagonist theophylline prevented renal 
ischaemic damage in rabbits [161]. In human 
studies, theophylline attenuated nephrotoxicity from 
contrast media while the nucleoside transport 
inhibitor dipyridamole augm ented the contrast 
media-induced reduction in glomerular filtration 
rate  [162].
PHARMACOLOGICAL INTERVENTIONS
To date, pharmacological interventions are 
primarily directed towards adenosine-m ediated 
effects, Pi- and P2-purinergic receptor agonists and 
antagonists with varying degrees o f selectivity have 
been described. For a detailed description, there are 
some excellent reviews on this topic [27].
A part from compounds that directly interact with 
the adenosine receptor, some drugs with an indirect 
action have been developed. These can enhance 
adenosine release (AICA riboside [163]) or reduce 
adenosine degradation by inhibiting cellular uptake 
of adenosine (e.g. nucleoside transport inhibitors 
such as nitrobenzylthioinosine, dipyridamole, dilazep 
and miofiazine derivatives like drafiazine [164]) or 
inhibiting adenosine deaminase activity (deoxicofor- 
mycin). In addition, some compounds facilitate the 
binding of adenosine to its receptor through an 
allosteric mechanism. These allosteric enhancers 
may have the theoretical advantage of a possible 
adenosine receptor subtype specificity [165]. What 
these indirectly acting drugs have in common is that 
they affect adenosine-mediated actions only at sites 
of endogenous adenosine release, thereby 
preventing those systemic side-cffects that are assoc­
iated with intravenous infusion of adenosine or its 
analogues* For example, low-grade nucleoside trans­
port inhibition is able to potentiate the forearm
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vasodilator response to adenosine infusion into the 
brachial artery w ithout inducing unwanted side- 
effects [113].
CONCLUSIONS
The naturally occurring purines adenosine and 
ATP can induce a variety of effects that are 
m ediated by receptors located on the plasma 
m em brane. Studies in vitro and animal studies in 
vivo indicate that A TP is released from sympathetic 
nerve endings and aggregating thrombocytes, and 
cun inducc vasoconstriction via stimulation o f Pax 
purinoceptors located on vascular smooth muscle 
cells and vasodilatation via receptors that are 
located on the endothelium  and to a small extent 
also on smooth muscle cells. A denosine, the major 
pharmacologically active breakdown product of 
ATP, can induce vasodilatation via endothelium- 
dependen t and endothelium -independent mechan­
isms. Furtherm ore, adenosine is able to reduce 
noradrenaline release from sympathetic nerve 
endings by a presynaptic mechanism. A denosine can 
protect the  heart against the  sequelae o f isehaemia 
and can induce ischaemic preconditioning. Many of 
these effects have now also been observed in
humans in vivo. Exploitation o f the  cardioprotective 
effects of endogenous adenosine is a major 
challenge for cardiovascular pharmacology, In this 
respect, specific low-grade nucleoside transport 
inhibition is veiy promising.
Im portan t progress has been m ade in the molec­
ular characterization of P2 purinoceptors. New 
insights into the structure o f these receptors should 
facilitate the developm ent of specific P> purino- 
ceptor antagonists and  agonists that could further 
characterize the physiological im portance of purines 
ia the regulation o f  various body functions and 
direct the design of pharm acological interventions of 
clinical benefit.
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